| abstract |
Described herein are NASH, NAFLD, and fibrosis biomarkers and methods for making a diagnosis (or diagnostic support) of NAFLD, NASH, and / or fibrosis. In addition, a method for distinguishing between NAFLD and NASH, a method for classifying fibrosis stages, a method for determining the severity of liver disease, a method for determining the severity of liver disease or fibrosis, and NASH, NAFLD, Methods for monitoring the progression / regression of and / or fibrosis are described herein. |